Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions and Restenosis From Prior Endovascular Procedures in This Sector.

I

iVascular

Status

Completed

Conditions

Peripheral Vascular Disease

Treatments

Device: Paclitaxel-eluting balloon

Study type

Observational

Funder types

Industry

Identifiers

NCT02458911
Luminor

Details and patient eligibility

About

The purpose of the study is to obtain data regarding safety and efficacy of drug-eluting balloon luminor 14 & luminor 35 in the treatment of infrainguinal occlusive lesions (superficial femoral artery (SFA), popliteal artery (PA) and tibial arteries (ATs)) and restenosis from prior endovascular procedures in this sector.

Enrollment

214 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients of both sexes aged at least 18

Primary injuries and restenosis of the infrainguinal sector of AFS, AP and ATs, and intrastent restenosis or post-ATP prior in that sector.

  • Stenosis >50% and occlusions. (image test)
  • Length: 20 to 200 mm
  • Artery diameter: 2-7 mm.
  • Symptomatic patients (grades 2-5 Rutherford-Baker both included; Fontaine II-IV), affected in their quality of life and that accept treatment (moderate / severe claudication patients, critical ischemia without gangrene or injuries severe enough to foresee limb amputation).

Exclusion criteria

  • Patients with acute or subacute ischemia will be excluded.
  • Existence of flow-limiting lesions in arteries of the "in flow" or the "out flow" of the sector or artery under treatment (> 50 % of the arterial diameter).
  • Aneurysmal dilatation in the ipsilateral arterial axis.
  • Intolerance / allergy to heparin, thienopyridine derivatives (clopidogrel , ticlopidine) and aspirin.
  • Hemorrhagic diathesis during the 3 months prior to inclusion.
  • Patients with a life expectancy of less than 12 months.
  • Serious allergy to contrasts or PTX.
  • Inability to cross the lesion with the guide (these cases will be recorded for the analysis as "intention to treat).
  • Those participating simultaneously in another clinical trial.
  • Pregnancy or lactation (pregnancy tests on fertiles).

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems